Towards Healthcare Research & Consulting

Animal Gastroesophageal Reflux Disease Market Size, Share, Forecast (2026-2035), Acid Suppressants, Prokinetics, Therapeutic Diets and Diagnostics for Dogs, Cats, Horses and Livestock

The animal gastroesophageal reflux disease (GERD) market is estimated at USD 4.02 billion in 2026 and is forecasted to reach USD 8.11 billion by 2035, growing at a CAGR of 8.10% from 2026 to 2035. The market accounted for USD 3.72 billion in 2025, which is the base year. The market comprises products and services used for diagnosis and treatment of reflux of stomach contents into the oesophagus and related upper gastrointestinal conditions in animals, including proton pump inhibitors, H2 receptor blockers, antacids, prokinetic agents and mucosal protectants, therapeutic gastrointestinal diets, and diagnostic tests, endoscopy and imaging, used in companion animals such as dogs, cats and horses and in production animals. Treatment accounted for the largest product share of 54.60% in 2025, because acid-suppressing drugs, prokinetics, and prescription gastrointestinal diets are used repeatedly in managing reflux, oesophagitis, and related digestive disorders. North America accounted for 40.80% of revenue in 2025, owing to high pet ownership and veterinary spending, pet insurance, and wide use of advanced diagnostics and prescription diets. The market demand is being driven by rising pet ownership and humanization, an ageing pet population, greater awareness of digestive disease in dogs, cats and horses, gastric ulcer and reflux management in performance horses, advances in veterinary endoscopy and imaging, and growth in therapeutic nutrition. Animal health and pet nutrition companies are launching new gastrointestinal diets, microbiome-based nutrition and enhanced formulations, while drug developers are investigating veterinary prokinetics.

Last updated 3 November 2026   |   Primary source: Towards Healthcare   |   Report: 7147   |   Derived values are labelled
USD 4.02 Bn
Revenue, 2026
USD 8.11 Bn
Forecast, 2035
8.10%
CAGR, 2026-2035
Global
Report Coverage

Key Takeaways

Animal Gastroesophageal Reflux Disease Market Snapshot, Comparision and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 3.72 billion
  • Estimated market size in 2026: USD 4.02 billion
  • Projected market size by 2035: USD 8.11 billion
  • CAGR (2026–2035): 8.10%

Regional Market Spotlight

  • North America dominated the market with a 40.80% (USD 1.52 billion) share in 2025.
  • Europe accounted for 27.60% (USD 1.03 billion) of the market in 2025.
  • Asia Pacific held 22.60% (USD 0.84 billion) of revenue in 2025 and is projected to expand at the highest CAGR of 9.41% during the forecast period.

Segmental Spotlight

  • By product, Treatment held a market share of 54.60% (USD 2.03 billion) in 2025.
  • By treatment type, the Proton Pump Inhibitors segment accounted for 31.40% (USD 1.17 billion) of revenue in 2025.
  • By animal, Companion Animals accounted for a 71.20% (USD 2.65 billion) share in 2025.
  • Veterinary Hospitals & Clinics accounted for 62.40% (USD 2.32 billion) of revenue in the distribution channel category in 2025.

The market is projected to expand from USD 3.72 billion in 2025 to USD 8.11 billion by 2035 because more and more pets are being diagnosed and treated for reflux and related digestive disorders as owners are spending more on veterinary care, and therapeutic diets and acid-suppressing drugs are used long term. Advancements in veterinary endoscopy and imaging, pet insurance coverage, and new microbiome-based gastrointestinal diets drive consistent growth, propelling the market to USD 5.49 billion by 2030 and maintaining a CAGR of 8.10% during the forecast period.

Animal Gastroesophageal Reflux Disease Market Size is USD 4.02 Billion in 2026.

Analyst View: We built the estimate from the number of animals diagnosed with reflux and related upper gastrointestinal disorders by species and region, multiplied by spending on drugs, therapeutic diets and diagnostic procedures per case, together with livestock treatment volumes. Case numbers highlight pet populations, veterinary visit rates, diagnostic adoption and equine and livestock management practices. The total was cross-checked against the gastrointestinal product revenue of prominent animal health, pet nutrition and veterinary diagnostics companies and against published estimates, which places our base year slightly above the highest comparable figure. The growth rate reflects growing veterinary care spending. The market demand is being negatively influenced by generic drug pricing and limited approved veterinary-specific GERD drugs.

  • Fresh and wet therapeutic diets are expanding.
  • Veterinary endoscopy adoption rises.
  • Online pharmacies distribute GI products.
  • Equine ulcer and reflux management grows.

Drivers, Restraints and Opportunities

Driver: Pet ownership and humanization are rising. Increasing population of ageing pets drives demand as they develop relatively more digestive disorders. Owners are spending more on veterinary diagnostics and treatment, and pet insurance improves treatment accessibility. Therapeutic nutrition is widely recommended.

Restraint: Few drugs have been approved specifically for veterinary GERD. Diagnosis can be pricey and involve significant intricacies. Generic human drugs limit pricing power, and there is significant variation in owner compliance with long-term diets. Economic pressure can reduce discretionary veterinary spending.

Opportunity: Veterinary-specific prokinetics and formulations have the ability to cater to unmet needs. Microbiome diagnostics can be used to provide personalized treatment. Pet market expansion in Asia offers rapid growth opportunity. Telehealth and online pharmacies improve access, and equine performance markets fuel demand for premium products.

Market Segmentation: 2025 Share and Value

Animal Gastroesophageal Reflux Disease Market by Product 2025 Share & Size

Segments 2025 Share 2025 Market Value
Treatment 54.60% USD 2.03 billion
Diagnostics 45.40% USD 1.69 billion

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Treatment accounted for 54.60% (USD 2.03 billion) of revenue in 2025 because reflux and oesophagitis need ongoing acid suppression, prokinetic therapy, and dietary management. The diagnostics segment held a market share of 45.40% (USD 1.69 billion), and its coverage spans laboratory tests, endoscopy, radiography, and ultrasound used to confirm reflux and rule out any possibility of other conditions.

Animal Gastroesophageal Reflux Disease Market by Treatment Type 2025 Share & Size

Segments 2025 Share 2025 Market Value
Proton Pump Inhibitors 31.40% USD 1.17 billion
Therapeutic Diets & Others 23.40% USD 0.87 billion
H2 Receptor Blockers 18.60% USD 0.69 billion
Prokinetic Agents 14.40% USD 0.54 billion
Antacids 12.20% USD 0.45 billion

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Proton pump inhibitors accounted for a 31.40% (USD 1.17 billion) share in 2025 because omeprazole and similar drugs are acid suppressants with the highest effectiveness for dogs, cats, and horses, including approved equine omeprazole products for gastric ulcers. Therapeutic diets and others held a market share of 23.40% (USD 0.87 billion), and are growing at the highest rate in the treatment-type segment owing to new prescription gastrointestinal diets. H2 receptor blockers account for 18.60% (USD 0.69 billion) of revenue, prokinetic agents for 14.40% (USD 0.54 billion), and antacids for 12.20% (USD 0.45 billion).

Animal Gastroesophageal Reflux Disease Market by Animal 2025 Share & Size

Segments 2025 Share 2025 Market Value
Companion Animals 71.20% USD 2.65 billion
Livestock 28.80% USD 1.07 billion

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Companion animals accounted for 71.20% (USD 2.65 billion) share in 2025 because dogs, cats and horses account for a major proportion of diagnostic work-ups and long-term treatment. Livestock held 28.80% (USD 1.07 billion) of net market revenue, covering digestive health management in cattle, swine and poultry.

Animal Gastroesophageal Reflux Disease Market by Distribution Channel 2025 Share & Size

Segments 2025 Share 2025 Market Value
Veterinary Hospitals & Clinics 62.40% USD 2.32 billion
Retail Pharmacies 21.20% USD 0.79 billion
E-commerce 16.40% USD 0.61 billion

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Veterinary hospitals and clinics accounted for a 62.40% (USD 2.32 billion) share in 2025 because diagnosis, prescription drugs, and therapeutic diets are provided through veterinarians. Retail pharmacies held a market share of 21.20% (USD 0.79 billion), and e-commerce held 16.40% (USD 0.61 billion) and is the fastest-growing channel due to the expansion of online veterinary pharmacies.

Analyst View: Segment values were allocated by matching cases, treatment patterns, and spending to products, treatment types, animals, and channels, using company revenue mixes and veterinary data. Treatment, PPIs, companion animals and veterinary clinics hold a leading position because of well-established care pathways. We expect the shares of therapeutic diets and e-commerce to increase.

Regional Analysis

Animal Gastroesophageal Reflux Disease Market by Region 2025 Share & Size

Region 2025 Share 2025 Market Value
North America 40.80% USD 1.52 billion
Europe 27.60% USD 1.03 billion
Asia Pacific 22.60% USD 0.84 billion
Latin America 5.20% USD 0.19 billion
Middle East & Africa 3.80% USD 0.14 billion

Note: 2025 is the base year.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

North America held 40.80% (USD 1.52 billion) of revenue in 2025. In July 2026, Royal Canin launched fresh therapeutic diets, including a low-fat gastrointestinal formula, in the United States, which caters to the high-demand regional market as it facilitates GI transit.

Europe accounted for a market share of 27.60% (USD 1.03 billion) in 2025. Equine gastric ulcer and reflux management is significant, and the veterinary diagnostics ecosystem is well-developed.

Asia Pacific held 22.60% (USD 0.84 billion) of revenue in 2025 and is growing at the highest rate. China's pet population and veterinary hospital chains are experiencing rapid expansion.

Latin America accounted for a 5.20% (USD 0.19 billion) share in 2025. Brazil has a large pet population and livestock sector.

The Middle East and Africa held 3.80% (USD 0.14 billion) of the market in 2025. Equine care in the Gulf and rising pet ownership drive regional market demand.

Analyst View: Regional shares were built from cases and spending in each region. North America dominates because of veterinary spending and insurance. We assign Asia Pacific the highest growth premium because pet ownership and veterinary services are expanding at the fastest rate in this region.

Competitive Landscape

Top 10 Companies in the Animal Gastroesophageal Reflux Disease Market, 2025

Rank Company Name Market-Specific Revenue (USD Billion) 2025 Share Key Products / Business Headquarters
1 Hill's Pet Nutrition 0.42 11.29% Prescription Diet i/d gastrointestinal diets United States
2 Royal Canin 0.40 10.75% Gastrointestinal veterinary diets France
3 Zoetis 0.22 5.91% Gastrointestinal therapeutics and diagnostics United States
4 Purina 0.20 5.38% Pro Plan Veterinary Diets EN Gastroenteric United States
5 IDEXX Laboratories 0.18 4.84% Veterinary diagnostics and imaging United States
6 Boehringer Ingelheim 0.16 4.30% GastroGard equine omeprazole Germany
7 Elanco 0.14 3.76% Digestive health products United States
8 Merck Animal Health 0.12 3.23% Animal health therapeutics United States
9 Virbac 0.08 2.15% Digestive support products France
10 Vetoquinol 0.06 1.61% Gastrointestinal care products France

Note: Company revenues and shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Hill's Pet Nutrition led the market with 11.29% (USD 0.42 billion) of revenue in 2025, followed by Royal Canin at 10.75% (USD 0.40 billion) and Zoetis at 5.91% (USD 0.22 billion). The dominance of Hill's Pet Nutrition can be attributed to its Prescription Diet gastrointestinal range, including i/d, widely recommended by veterinarians for digestive disorders. Royal Canin offers a broad portfolio of gastrointestinal veterinary diets, recently extended with fresh therapeutic diets, and Zoetis is an important supplier of gastrointestinal therapeutics and diagnostics to veterinary practices. Purina, IDEXX Laboratories, Boehringer Ingelheim, Elanco, Merck Animal Health, Virbac and Vetoquinol compete through therapeutic diets, diagnostics and imaging, equine omeprazole, digestive health products and regional portfolios. The top 10 companies accounted for 53.23% (USD 1.98 billion) of share in 2025, while the remaining 46.77% (USD 1.74 billion) was shared among generic drug suppliers, compounding pharmacies, imaging and endoscopy manufacturers and regional pet food brands. The market is moderately concentrated, and competition revolves around clinical evidence, veterinarian recommendation, palatability and compliance for diets, drug formulation and approvals, diagnostic accuracy, and distribution through clinics and online pharmacies. Many acid-suppressing drugs are human generics used off-label, limiting differentiation for drug manufacturers.

Companies Ecosystem

The animal GERD ecosystem links ingredient and active pharmaceutical suppliers with animal health and pet nutrition companies, diagnostic and imaging providers, distributors, and veterinary practices.

Ecosystem Stage Role in the Market Key Companies
Ingredients & APIs Supply drug actives and nutrition ingredients API manufacturers, fibre and probiotic suppliers
Drug & Nutrition Companies Develop drugs and therapeutic diets Hill's, Royal Canin, Purina, Zoetis, Boehringer Ingelheim, Elanco
Diagnostics & Imaging Provide tests, endoscopes and imaging IDEXX, Antech, endoscopy and ultrasound makers
Distributors & Pharmacies Distribute products to clinics and owners Veterinary distributors, online pet pharmacies
Veterinary Practices & Owners Diagnose and treat animals Veterinary hospitals, equine practices, pet owners, farmers

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant positions key participants in the market by market strength, reflecting revenue scale, market share, and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, intensity of research and development, and collaborations. Positions reflect each company's 2025 animal GERD revenue and our evaluation of its product innovation, clinical evidence, and distribution.

Leaders: Hill's Pet Nutrition, Royal Canin, Zoetis, Purina, and IDEXX Laboratories bring together significant gastrointestinal revenue and strong veterinary recommendation, new product launches, and broad distribution.

Innovators: Elanco brings digestive health and microbiome-focused products that are being increasingly used in the veterinary segment.

Niche Players: Boehringer Ingelheim, Merck Animal Health, Virbac, and Vetoquinol serve specific therapeutic or regional segments.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Recent Developments

  • July 2026: Royal Canin launched Royal Canin Fresh Veterinary Diets in the United States, including a Gastrointestinal Low-Fat formula for dogs, available only through veterinarians.
  • January 2025: Hill's Pet Nutrition introduced new Prescription Diet products with its ActivBiome+ microbiome technology, including Digestion variants and i/d for puppies and kittens.

Market Segments

By Product

  • Treatment
  • Diagnostics

By Treatment Type

  • Proton Pump Inhibitors
  • Therapeutic Diets & Others
  • H2 Receptor Blockers
  • Prokinetic Agents
  • Antacids

By Animal

  • Companion Animals
  • Livestock

By Distribution Channel

  • Veterinary Hospitals & Clinics
  • Retail Pharmacies
  • E-commerce

By Region

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Spain, Rest of Europe)
  • Asia Pacific (China, Japan, India, South Korea, Taiwan, Rest of Asia Pacific)
  • Latin America (Brazil, Argentina, Rest of Latin America)
  • Middle East & Africa (GCC, South Africa, Rest of MEA)

Research Methodology

The market is defined as drugs, therapeutic diets, and diagnostic products and procedures for gastroesophageal reflux and related upper gastrointestinal disorders in companion and production animals. The 2025 base year was built bottom-up from animals diagnosed with reflux and related disorders by species and region and spending on drugs, diets, and diagnostics per case, and checked top-down against the gastrointestinal product revenue of prominent animal health, pet nutrition, and veterinary diagnostics players. Segment, regional and company values were allocated from products, treatment types, animals, distribution channels and regional demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026–2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: The market growth can be attributed to veterinary care spending, combining therapeutic diets, acid-suppressing drugs, and diagnostics. Our estimate links demand to cases, treatment patterns, and spending, so the forecast follows pet ownership, veterinary visits, and nutrition innovation. The main upside comes from therapeutic diets and Asian pet markets, while the main risks are generic pricing and limited veterinary-specific drugs.

References

FAQ

Finding : The market was valued at USD 3.72 billion in 2025 and is estimated at USD 4.02 billion in 2026. It is projected to reach USD 8.11 billion by the end of the forecast period.

Finding : The market is expected to expand at a CAGR of 8.10% during the forecast period, owing to rising pet ownership, ageing pets, veterinary diagnostics, and therapeutic nutrition.

Finding : Treatment dominates the market with a 54.60% share in 2025, because acid-suppressing drugs, prokinetics, and prescription gastrointestinal diets are used repeatedly in managing reflux.

Finding : North America leads the market as it held 40.80% of revenue in 2025, while Asia Pacific is growing at the fastest rate.

Finding : Some of the key players in the market include Hill\'s Pet Nutrition, Royal Canin, Zoetis, Purina, IDEXX Laboratories, Boehringer Ingelheim, Elanco, Merck Animal Health, and Virbac.

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar